← All trials
NCT06214130
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 22, 2023
- Primary completion
- Nov 6, 2023
- Completion date
- Nov 18, 2023
- First posted
- Jan 19, 2024
- Last posted
- Jan 23, 2024
- Enrollment
- 22
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Desitin Arzneimittel GmbHLead sponsor
- BioPharma ServicesOfficial
- BioPharma ServicesCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.